Get started
Author

Nathan F. Schachter

Observed name: Nathan Schachter
Observed institutions: Ontario Institute for Cancer Research, University Health Network, University of Toronto, Hospital for Sick Children, AbbVie Canada (Canada), Donnelly Centre for Cellular and Biomolecular Research
ORCID: 0000-0002-6747-8207
Observed ORCID: 0000-0002-6747-8207
OpenAlex ID: A5065963132
Elevated PI3K signaling drives multiple Breast Cancer subtypes
2011 · Jessica R. Adams, Nathan F. Schachter, et al. · Oncotarget · 53
PDF
shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2014 · Tao Deng, Jeff C. Liu, et al. · Cancer Research · 39
The Chromatin Regulator Ankrd11 Controls Palate and Cranial Bone Development
2021 · Daniela Marta Roth, Pranidhi Baddam, et al. · Frontiers in Cell and Developmental Biology · 31
PDF
NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program
2019 · Nika Maani, Shelley Westergard, et al. · Cancers · 29
PDF
Comprehensive characterization of a Canadian cohort of von Hippel‐Lindau disease patients
2019 · Yasser Salama, Saleh Albanyan, et al. · Clinical Genetics · 26
Single allele loss-of-function mutations select and sculpt conditional cooperative networks in breast cancer
2021 · Nathan F. Schachter, Jessica R. Adams, et al. · Nature Communications · 14
PDF
Healthcare resource use in the management of advanced epithelial ovarian cancer in Canada.
2025 · Kimberly Guinan, Laurie Demers-Rozon, et al. · Journal of Clinical Oncology
Data from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
Supplementary Figure 6 from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
Supplementary Figure 5 from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
Supplementary Figure 7 from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
PDF
Supplementary Figure 4 from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
PDF
Supplementary Figure 1 from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
Supplementary Figure 2 from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
Supplementary Figure 3 from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
PDF
Supplementary Table 1 from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
PDF
Supplementary Table 2B from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
Supplementary Table 4B from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
Supplementary Table 3 from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
Supplementary Figure Legends from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
Supplementary Table 2A from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
Supplementary Table 4A from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
Data from shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
2023 · Tao Deng, Jeff C. Liu, et al.
Author response for "Comprehensive Characterization of a Canadian Cohort of von Hippel‐Lindau Disease Patients"
2019 · Yasser Salama, Saleh Albanyan, et al. · Publons reviews and discussion
Author response for "Comprehensive Characterization of a Canadian Cohort of von Hippel‐Lindau Disease Patients"
2019 · Yasser Salama, Saleh Albanyan, et al. · Publons reviews and discussion
Works count: 26
Citation count: 192
H-index: 6
I10-index: 6
Year
Topic
Type